Literature DB >> 32247648

Fibroblast Growth Factor-23 and a Vegetarian Diet.

Shuchi Anand1, Ram Jagannathan2, Ruby Gupta3, Sailesh Mohan3, Dorairaj Prabhakaran3, Myles Wolf4.   

Abstract

OBJECTIVE: Sparse data exist on population distributions of serum fibroblast growth factor-23 (FGF23) levels from developing, middle-income economies. FGF23 levels may differ substantially across regions based on differences in diet and urbanization. In a population-based study from North India, we tested the hypothesis that urinary phosphate excretion and FGF23 levels are lower among rural compared with urban participants, and among vegetarian compared with nonvegetarian participants.
METHODS: We measured 24-hour urinary phosphate, and serum parathyroid hormone and FGF23 in a subsample of the population-based Cardiometabolic Risk Reduction in South Asia and Indian Council of Medical Research Coronary Heart Disease surveys. We categorized participants according to diet and residence: urban nonvegetarians (n = 70), urban vegetarians (n = 564), and rural vegetarians (n = 558). Using least square means, we compared the groups' 24-hour urinary phosphate (with urban vegetarians as reference) and FGF23 levels after accounting for age, sex, diabetes, and body mass index.
RESULTS: Among 1,192 study participants, mean FGF23 was 41 ± 18 pg/mL, median parathyroid hormone was 44 (interquartile range [IQR] 31-60) pg/mL, and median 24-hour urinary phosphate excretion was 419 (IQR: 47-622) mg/day. Urinary phosphate was significantly higher in rural compared with urban vegetarians (median, 503; IQR, 334-543 versus 365; IQR, 199-399 mg/day), but adjusted mean FGF23 levels did not differ across study groups.
CONCLUSION: In rural and urban India, urinary phosphate excretion was low, but FGF23 levels did not differ by residence or dietary preference. Homogenously low dietary phosphate intake across different settings and diets may partly explain the lack of differences in FGF23.
Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32247648      PMCID: PMC7529717          DOI: 10.1053/j.jrn.2020.02.004

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  33 in total

1.  Differences in 24-hour urine composition between black and white women.

Authors:  Eric N Taylor; Gary C Curhan
Journal:  J Am Soc Nephrol       Date:  2007-01-10       Impact factor: 10.121

2.  Longitudinal FGF23 Trajectories and Mortality in Patients with CKD.

Authors:  Tamara Isakova; Xuan Cai; Jungwha Lee; Dawei Xie; Xue Wang; Rupal Mehta; Norrina B Allen; Julia J Scialla; Michael J Pencina; Amanda H Anderson; John Talierco; Jing Chen; Michael J Fischer; Susan P Steigerwalt; Mary B Leonard; Chi-Yuan Hsu; Ian H de Boer; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2017-11-22       Impact factor: 10.121

3.  Twenty-Four-Hour Urine Phosphorus as a Biomarker of Dietary Phosphorus Intake and Absorption in CKD: A Secondary Analysis from a Controlled Diet Balance Study.

Authors:  Elizabeth R Stremke; Linda D McCabe; George P McCabe; Berdine R Martin; Sharon M Moe; Connie M Weaver; Munro Peacock; Kathleen M Hill Gallant
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-19       Impact factor: 8.237

4.  Serum creatinine as marker of kidney function in South Asians: a study of reduced GFR in adults in Pakistan.

Authors:  Tazeen H Jafar; Christopher H Schmid; Andrew S Levey
Journal:  J Am Soc Nephrol       Date:  2005-03-30       Impact factor: 10.121

5.  Fibroblast growth factor-23 and cardiovascular events in CKD.

Authors:  Julia J Scialla; Huiliang Xie; Mahboob Rahman; Amanda Hyre Anderson; Tamara Isakova; Akinlolu Ojo; Xiaoming Zhang; Lisa Nessel; Takayuki Hamano; Juan E Grunwald; Dominic S Raj; Wei Yang; Jiang He; James P Lash; Alan S Go; John W Kusek; Harold Feldman; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2013-10-24       Impact factor: 10.121

6.  20-Year Trend of CVD Risk Factors: Urban and Rural National Capital Region of India.

Authors:  Dorairaj Prabhakaran; Ambuj Roy; Pradeep A Praveen; Lakshmy Ramakrishnan; Ruby Gupta; Ritvik Amarchand; Dimple Kondal; Kalpana Singh; Meenakshi Sharma; Deepak Kumar Shukla; Nikhil Tandon; Kolli Srinath Reddy; Anand Krishnan
Journal:  Glob Heart       Date:  2017-04-11

7.  Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Authors:  Rodrigo B Oliveira; Ana L E Cancela; Fabiana G Graciolli; Luciene M Dos Reis; Sérgio A Draibe; Lilian Cuppari; Aluizio B Carvalho; Vanda Jorgetti; Maria E Canziani; Rosa M A Moysés
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-12       Impact factor: 8.237

8.  Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.

Authors:  Vincent M Brandenburg; Marcus E Kleber; Marc G Vervloet; Andreas Tomaschitz; Stefan Pilz; Tatjana Stojakovic; Graciela Delgado; Tanja B Grammer; Nikolaus Marx; Winfried März; Hubert Scharnagl
Journal:  Atherosclerosis       Date:  2014-08-28       Impact factor: 5.162

9.  Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community.

Authors:  Johan Ärnlöv; Axel C Carlsson; Johan Sundström; Erik Ingelsson; Anders Larsson; Lars Lind; Tobias E Larsson
Journal:  Kidney Int       Date:  2012-09-05       Impact factor: 10.612

10.  Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

Authors:  Majd A I Mirza; Anders Larsson; Håkan Melhus; Lars Lind; Tobias E Larsson
Journal:  Atherosclerosis       Date:  2009-05-21       Impact factor: 5.162

View more
  1 in total

Review 1.  The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations.

Authors:  Annemieke C Heijboer; Etienne Cavalier
Journal:  Calcif Tissue Int       Date:  2022-06-04       Impact factor: 4.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.